Safety, Tolerability and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced GC or GEJ Cancer.
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, single-arm, dose escalation and dose expansion Phase
I/IIa study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2
dose (RP2D), and the safety and tolerability profile along with preliminary signs of efficacy
of rivoceranib in combination with paclitaxel as a second-line therapy in advanced, recurrent
and/or metastatic gastric or gastroesophageal junction cancer. This study will also
characterize the pharmacokinetic (PK) parameters of rivoceranib and paclitaxel when given in
combination.